MOTS-c is a short peptide of 16 amino acids that the body makes naturally. It is not FDA-approved for any use, and no approved medicine in the United States contains it.
Unusually, the code for MOTS-c is stored in mitochondrial DNA, the small set of genes inside mitochondria, rather than in the DNA of the cell nucleus. Its name stands for mitochondrial open reading frame of the 12S rRNA type-c, which describes where that code sits. It belongs to a group called mitochondrial-derived peptides, which also includes humanin.
MOTS-c was first described in 2015 by researchers in the United States, in the journal Cell Metabolism. In mice, its main target appeared to be skeletal muscle. In cells, it interfered with the folate pathway and the production of purines, which led to activation of AMPK, an enzyme that acts as a sensor of the cell's energy supply.
Most MOTS-c research has been done in cells and animals. Two widely cited studies:
Human studies of MOTS-c have mostly measured the body's own levels, not the effects of giving it as a drug. In its compounding review, the FDA stated that it had not identified any human exposure data for drug products containing MOTS-c. Early laboratory findings often do not hold up in people, which is why controlled clinical trials are required before any drug can be approved.
A related compound, CB4211, is a modified analog of MOTS-c developed by the company CohBar. A phase 1a/1b study that enrolled 88 participants, including healthy volunteers and people with nonalcoholic fatty liver disease, was completed in 2021, and the company reported that it met its primary goal of safety and tolerability. CB4211 is a different molecule, it has not been approved, and its results cannot be applied to MOTS-c.
Current status: Not FDA-approved.
MOTS-c was previously on the FDA's Category 2 list of bulk substances that raise significant safety concerns for compounding. The FDA cited a possible significant risk of immunogenicity (an unwanted immune response) and difficulties with peptide impurities. As of the FDA's April 2026 update, the nomination is listed as withdrawn and MOTS-c is no longer in Category 2.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7 to 5, with 2 abstentions, to recommend adding MOTS-c to the 503A Bulks List, the list of bulk substances pharmacies may use for compounding, for obesity and osteoporosis. FDA staff had recommended against it. The committee's vote is advisory only. The FDA must still make its own decision and complete formal rulemaking before pharmacies could use the substance, and as of late August 2026 it had not done so. Being placed on that list would allow compounding with a prescription; it would not make a substance an FDA-approved drug.
Because MOTS-c is not an approved drug, the FDA has not reviewed the contents or quality of products sold under the MOTS-c name.
The World Anti-Doping Agency (WADA) 2026 Prohibited List names MOTS-c as an activator of AMPK under class S4 (hormone and metabolic modulators). It is prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply, prepare or distribute MOTS-c in any form, and nothing on this page should be read as an offer.
If you have questions about MOTS-c or a related health concern, talk to a licensed healthcare provider who knows your medical history.
See the full list of compound profiles in the Peptide Guide. Related profiles: humanin, another mitochondrial-derived peptide, and SS-31 (elamipretide). For background, read what peptides are.